ARA-290, also referred to in the literature by the International Nonproprietary Name cibinetide, is a synthetic 11-amino-acid peptide engineered from the tertiary structure of human erythropoietin. AminoOptimization Group supplies it as a lyophilised research powder in a 10 mg presentation, tested to 99% purity by HPLC, with a Certificate of Analysis available for the lot supplied. This material is offered strictly for laboratory research use. It is not a drug, and it is not for human or veterinary use.
What is ARA-290?
ARA-290 is not a fragment of erythropoietin’s linear sequence so much as a reconstruction of one surface of it. Erythropoietin (EPO) is a 165-amino-acid glycoprotein whose activity depends on the three-dimensional presentation of several discontinuous regions, one of which — the “helix B” surface — is reproduced here as a short, independently folded 11-residue peptide. Reducing a 165-residue protein to an 11-residue peptide is the structural basis for the compound’s distinct receptor profile relative to native EPO.
That distinct profile is described in the literature through the “innate repair receptor” (IRR) hypothesis. Classical erythropoietic signalling proceeds through a homodimer of the erythropoietin receptor, (EPOR)2. The IRR is instead proposed as a heteromeric complex of EPOR and the beta common receptor (CD131), a subunit shared with GM-CSF, IL-3, and IL-5 receptor signalling. ARA-290 is studied specifically for engaging this heteromeric complex while showing negligible activity at the (EPOR)2 homodimer responsible for red blood cell production — a selectivity profile used in research to separate EPO’s tissue-signalling effects from its haematopoietic ones.
ARA-290 sits within a broader family of erythropoietin-derived, non-erythropoietic peptides examined for this same selectivity. Related analogues in the published literature carry different N-terminal or backbone modifications intended to alter enzymatic stability, and comparisons across the family are used to map which structural features of the helix-B surface are necessary for IRR engagement versus which are dispensable.
Specifications
- Compound: ARA-290 (cibinetide)
- CAS number: 1208243-50-8
- Molecular formula: C51H84N16O21
- Molecular weight: 1257 g/mol
- Purity: 99% HPLC
- Presentation: Lyophilised powder, sealed vial
- Available sizes: 10 mg
- Physical form: White to off-white powder
- Classification: Research peptide — not for human or veterinary use
Research context
Published research on ARA-290 centres on the innate repair receptor hypothesis: whether selective IRR engagement, without meaningful activation of the (EPOR)2 homodimer, is sufficient to reproduce the tissue-signalling component of EPO biology while leaving erythropoietic parameters unaffected. Study designs commonly report haematocrit, haemoglobin, and reticulocyte counts alongside the primary endpoint, specifically as a check on receptor selectivity rather than as the variable of interest.
Downstream of receptor binding, literature on this peptide examines activation of JAK2-associated intracellular signalling and its influence on pathways linked to cellular stress response and survival in various model systems. ARA-290 appears in study designs involving peripheral nerve structure, including small-fibre and corneal nerve fibre density as an anatomical readout, and in models probing metabolic and inflammatory signalling. Across these contexts, the peptide is generally used as a tool to interrogate the IRR pathway rather than as an endpoint in itself.
None of this literature establishes safety or efficacy for use in humans. It is provided as research context only.
Reconstitution
Lyophilised peptide requires reconstitution with a suitable sterile diluent before use in solution. Bacteriostatic water is the diluent most commonly specified for multi-use laboratory preparations; sterile water is typical for single-use work.
Direct the diluent stream against the inner wall of the vial rather than onto the powder itself, and allow the material to dissolve without agitation. Peptides are susceptible to shear stress — do not shake the vial. Swirl gently if needed, and expect full dissolution within a few minutes at room temperature.
Working concentration is a function of how much diluent is added to a given vial mass. Our peptide reconstitution calculator computes the resulting concentration for any combination of vial size and diluent volume.
Storage and stability
Before reconstitution: store the sealed vial in a freezer at -20 °C, protected from light. Lyophilised peptide is comparatively stable in this state. Brief excursions to ambient temperature during shipping are normal and are not expected to compromise a properly lyophilised product.
After reconstitution: refrigerate at 2–8 °C and protect from light. Reconstituted peptide in solution is materially less stable than the dry powder. Avoid repeated freeze-thaw cycles, which are a well-documented cause of aggregation and loss of measurable potency — aliquot instead if repeated sampling is required.
Inspect solutions before use. Cloudiness, visible particulate, or discolouration indicate the material should not be relied upon for quantitative work.
Certificate of Analysis
Every lot is tested by high-performance liquid chromatography, and the purity figure shown above refers to analytical results for the specific lot supplied — not to a generic specification. A Certificate of Analysis is available on request, and we will provide lot-specific documentation before purchase if your protocol requires it.
Purity by HPLC describes the proportion of the target peptide relative to detectable related substances. It is a statement about the material as manufactured and tested. It is expressly not a representation that the material is suitable for any use in humans or animals.
Handling and safety
Handle in accordance with good laboratory practice. Use appropriate personal protective equipment, work in a suitable containment environment, and dispose of material and consumables according to your institution’s requirements and applicable local regulation. Anyone with access to this material should understand that it is not for human or veterinary use.
Frequently asked questions
What is the difference between ARA-290 and erythropoietin?
Erythropoietin is a 165-amino-acid glycoprotein; ARA-290 is an 11-amino-acid peptide corresponding to one surface region of it. Literature describes ARA-290 as engaging the innate repair receptor while showing negligible activity at the receptor homodimer responsible for erythropoiesis, a selectivity not present in the full-length protein.
Is ARA-290 approved in Canada?
No. This compound has not been evaluated or authorised by Health Canada, the FDA, or any comparable regulatory authority. It carries no DIN or NPN, its safety and efficacy for human use have not been assessed, and it is supplied for laboratory research only.
How much diluent should be used?
That depends on the working concentration your protocol requires. Use the reconstitution calculator to work out the resulting concentration for your vial size.
How long is reconstituted material usable?
Stability in solution is shorter than in lyophilised form and depends on diluent, temperature, and handling. Refrigerate at 2–8 °C, protect from light, avoid freeze-thaw cycling, and validate stability for your own storage conditions if your work depends on it.
Do you provide a Certificate of Analysis?
Yes — lot-specific, available on request, including before purchase.
Research use only
This product is supplied solely for laboratory and scientific research. It is not a drug, food, cosmetic, or medical device, and it must not be administered to humans or animals. Nothing on this page is medical advice or a therapeutic claim. Full terms are set out in our Research Use Only Disclaimer.
Reviews
There are no reviews yet.